Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02074904 · ClinicalTrials.gov registry record · Phase 2

Topiramate's Effects on Heavy Drinking

A Phase 2 study, sponsored by University of Pennsylvania.

Terminated
Registry status
Phase 2
Development phase
1
Enrollment target

NCT02074904: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.

NCT02074904 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02074904, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.

TERMINATED
Registry status
Phase 2
Development phase
1 participants
Enrollment target

Study Summary

The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI) to examine the effects of topiramate on brain and behavioral responses in heavy drinkers to appetitive alcohol reminders (cues that motivate continued alcohol use and relapse). This project will yield novel findings on brain and behavioral responses to alcohol cues, the effects of topiramate on alcohol cue reactivity, and the mechanisms underlying topiramate's ability to blunt alcohol cue reactivity and heavy drinking.

Interventions

  • DRUG Placebo
  • DRUG Topiramate

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2015-05
Est. Completion 2017-03
Phase Phase 2

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT02074904

The ClinicalTrials.gov registry entry for NCT02074904 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02074904 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02074904 about?

NCT02074904 is a clinical study titled "Topiramate's Effects on Heavy Drinking". The proposed project will utilize perfusion functional magnetic resonance imaging (fMRI) to examine the effects of topiramate on brain and behavioral responses in heavy drinkers to appetitive alcohol reminders (cues that motivate continued alcohol use and relapse). This project will yield novel find...

What is the current status of trial NCT02074904?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-05. Estimated completion is 2017-03.

What interventions are being tested in trial NCT02074904?

The interventions under investigation include: Placebo (DRUG), Topiramate (DRUG).

Who is sponsoring clinical trial NCT02074904?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.